• Explore /
  • Poster
  • / Efficacy and safety of the PI3Kδ inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24).

Efficacy and safety of the PI3Kδ inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24).

Abstract Poster

Authors

null

John M. Pagel

Swedish Cancer Institute, Seattle, WA

John M. Pagel , Nishitha Reddy , Deepa Jagadeesh , Anastasios Stathis , Adam Steven Asch , Huda S. Salman , Vaishalee Padgaonkar Kenkre , Jacob Drobnyk Soumerai , Judith Llorin-Sangalang , Igor Gorbatchevsky , Joanne Li , Andrew David Zelenetz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02914938

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 7550)

DOI

10.1200/JCO.2021.39.15_suppl.7550

Abstract #

7550

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Ruemu Ejedafeta Birhiray

First Author: Andrew David Zelenetz

First Author: Umberto Vitolo

First Author: Martin H. Dreyling